メタジェンセラピューティクス
Tsuruoka, JP · 5 known investors
Metagen Therapeutics is a biotech venture developing fecal microbiota transplantation (FMT) drugs and medical services based on gut microbiome research and clinical findings. Its work includes drug development pipelines such as an oral FMT drug for ulcerative colitis, targeting the Japanese market.
BiotechDeep TechDigital Health
Founders & leadership
TN
Taku Nakahara代表取締役社長CEO (President & CEO)
JT
Jun TerauchiCSO
Investors · 5
Frequently asked questions
- What does メタジェンセラピューティクス do?
- Metagen Therapeutics is a biotech venture developing fecal microbiota transplantation (FMT) drugs and medical services based on gut microbiome research and clinical findings. Its work includes drug development pipelines such as an oral FMT drug for ulcerative colitis, targeting the Japanese market.
- Who are メタジェンセラピューティクス's investors?
- メタジェンセラピューティクス's investors include Dentsu Ventures, Fast Track Initiative, Global Brain, MIRAI SOUZOU, Nippon Venture Capital.
- Where is メタジェンセラピューティクス headquartered?
- メタジェンセラピューティクス is headquartered in Tsuruoka, JP.